| Apr 1 |
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
|
| Mar 28 |
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
|
| Mar 25 |
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
|
| Mar 21 |
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
|
| Mar 20 |
Tonix picks CMOs for potential launch of fibromyalgia drug
|
| Mar 20 |
Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
|
| Mar 19 |
Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
|
| Mar 12 |
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring
|
| Mar 12 |
TNXP: Tonmya™ May Launch Alongside Another New Fibromyalgia Treatment…
|
| Mar 11 |
Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia
|
